Keywords: zometa, cuts, risk, early-stage, breast, cancer, recurrence

Zometa cuts risk of early-stage breast cancer recurrence

Article | 22 September 2008

Print This

Novartis' Zometa (zoledronic acid) reduced the risk of local and distant recurrence in pre- and post-menopausal women with early-stage breast ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in